Literature DB >> 7507483

Human proinsulin conversion in the regulated and the constitutive pathways of transfected AtT20 cells.

J C Irminger1, F M Vollenweider, M Neerman-Arbez, P A Halban.   

Abstract

AtT20 (mouse pituitary corticotroph) cells were stably transfected with human proinsulin cDNA. Clone H12 displayed low basal release of insulin-like immunoreactivity (< 1% cell content/30 min) with 17-fold stimulation by isobutylmethylxanthine/forskolin. Clone H23, by contrast, showed higher basal release (2.8% cell content/30 min) and only 6-fold stimulation. To follow the kinetics of conversion and release of only newly synthesized proinsulin, cells were pulse-chased, and labeled proinsulin-related products were analyzed by high pressure liquid chromatography. In the cells of both clones, [3H]proinsulin was converted to insulin with des-31,32-split proinsulin as the only detectable intermediate. While basal release of labeled products from H12 cells was low (3%/60 min), it was rapid and elevated from H23 cells (12.5% by 30 min and 24.8% by 60 min of chase) with [3H]des-31,32-split proinsulin the predominant molecular form. Stimulation of [3H] insulin release increased with time, reaching 3.8-fold by 90 min of chase, whereas that of [3H]des-31,32-split proinsulin was approximately 1.5-fold regardless of the chase time. Rapid secretion of newly synthesized products that is insensitive to secretagogues is the hallmark of the constitutive pathway. Thus in H23 cells an unusually large amount of proinsulin is diverted to the constitutive pathway, where it is partially converted to des-31,32-split proinsulin before release.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7507483

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Mutant proinsulin that cannot be converted is secreted efficiently from primary rat beta-cells via the regulated pathway.

Authors:  Philippe A Halban; Jean-Claude Irminger
Journal:  Mol Biol Cell       Date:  2003-03       Impact factor: 4.138

2.  Insulin secretion and insulin-producing tumors.

Authors:  Jean-Marc Guettier; Phillip Gorden
Journal:  Expert Rev Endocrinol Metab       Date:  2010-03-01

Review 3.  Sorting and storage during secretory granule biogenesis: looking backward and looking forward.

Authors:  P Arvan; D Castle
Journal:  Biochem J       Date:  1998-06-15       Impact factor: 3.857

4.  Proinsulin processing in the rat insulinoma cell line INS after overexpression of the endoproteases PC2 or PC3 by recombinant adenovirus.

Authors:  J C Irminger; K Meyer; P Halban
Journal:  Biochem J       Date:  1996-11-15       Impact factor: 3.857

5.  Inositol 1,4,5-trisphosphate receptor subtype 3 in pancreatic islet cell secretory granules revisited.

Authors:  M Ravazzola; P A Halban; L Orci
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

6.  Proinsulin endoproteolysis confers enhanced targeting of processed insulin to the regulated secretory pathway.

Authors:  R Kuliawat; D Prabakaran; P Arvan
Journal:  Mol Biol Cell       Date:  2000-06       Impact factor: 4.138

7.  Glucose effects on beta-cell growth and survival require activation of insulin receptors and insulin receptor substrate 2.

Authors:  Anke Assmann; Kohjiro Ueki; Jonathon N Winnay; Takahashi Kadowaki; Rohit N Kulkarni
Journal:  Mol Cell Biol       Date:  2009-03-09       Impact factor: 4.272

8.  Sequence requirements for proinsulin processing at the B-chain/C-peptide junction.

Authors:  J E Kaufmann; J C Irminger; P A Halban
Journal:  Biochem J       Date:  1995-09-15       Impact factor: 3.857

9.  Heterologous processing of rat prosomatostatin to somatostatin-14 by PC2: requirement for secretory cell but not the secretion granule.

Authors:  A S Galanopoulou; N G Seidah; Y C Patel
Journal:  Biochem J       Date:  1995-10-01       Impact factor: 3.857

Review 10.  Proinsulin processing in the regulated and the constitutive secretory pathway.

Authors:  P A Halban
Journal:  Diabetologia       Date:  1994-09       Impact factor: 10.122

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.